Starting in September, Egypt will be allowed to sell Sovaldi (sofosbuvir), Gilead Sciences' newest drug to treat the hepatitis C virus (HCV), for just one percent of its market price, thanks to a new deal reached between the pharmaceutical company and the nation's government, reports.

The agreement will provide the drug to Egyptians living with the virus for just LE2,200, or about $300, for a 12-week course of treatment. That's much lower than Gilead's initial offer to Egypt back in March, which was around $900 per treatment course.

The country currently has the highest prevalence of hepatitis C in the world; most of it linked to poorly sterilized needles dating back to the 1970s in widespread campaigns to eradicate the parasitic disease schistosomiasis. More than 12 million people in the country live with the virus.

Also in Egypt, the launch of a highly dubious device that the nation's military government claims can cure both hep C and HIV has been postponed for another six months.

To read the full article, click here.